Injectable immunotherapy shows promise for liver tumors – Healio
|
Injectable immunotherapy shows promise for liver tumors
Healio Talimogene laherparevec (T-VEC, Amgen) is a genetically modified HSV-1 oncolytic immunotherapy designed to preferentially replicate in tumors and produce granulocyte-macrophage colony-stimulating factor to stimulate anti-tumor immune responses … |
